Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Tetsuya Tsukamoto

Shigenori Ohkawa

Taku Kamei

Takeshi Wakabayashi

Tadatoshi Hashimoto

Mika Goto

Yusuke Ohba

Taiichi Ohra

Yoshihiro Kiyota

Masato Shimojou

Masaki Setou

Shouzou Yamamoto

Minoru Nakamura

Tatsuki Koike

Makoto Kamata

Yasutaka Hoashi

Norihito Tokunaga

Masami Yamada

Yuichi Kajita

Masaomi Miyamoto

Yoshihide Tomata

Ikuo Fujimori

Takafumi Takai

Nobuki Sakauchi

Tomoya Yukawa

Morihisa Saitoh

Yukio Ishibashi

Takafumi Yukawa

Yuji Ishichi

Yoshihisa Nakada

Masahiro Okura

Yoshiharu Maeda

Hiroyuki Nagamiya

Masahiro Mizuno

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted bromopiperazine ring; Rand Rare the same or different from each other, and represent a hydrogen atom or optionally substituted lower alkyl; Rand Rare the same or different from each other, and represent a hydrogen atom or halogenated or non-halogenated lower alkyl; Rto Rare the same or different from each other, and represent a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted aromatic heterocyclic ring, optionally substituted amino, or acyl; and represents a single bond or double bond, wherein Rand Rdo not exist when carbon atoms respectively adjacent to R: and Rform a double bond, and there is no case where all of Rto Rare hydrogen atoms, and Rand R; may form a ring together with an adjacent carbon atom; or a salt thereof. 

Benzofuran derivatives

The present invention provides a heterocycle derivative having a superior amyloid &#x3b2; production inhibitory activity and/or a superior &#x3b3;-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Heterocyclic compound and use thereof

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

Heterocyclic compounds

The present invention provides a compound represented by the following formula (I): wherein:

A cannabinoid receptor modulator containing a compound represented by Formula (I) wherein, X is an oxygen atom, etc., Ris an optionally substituted acylamino group, ring Ais a benzene ring which may further have a substituent in addition to R, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof.

Cannabinoid receptor modulator

A compound represented by the formula: (wherein, Rand Rare the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or Rand Rmay form, together with the adjacent carbon atom, a 3&#x2013;8 membered iso- or heterocyclic group, Rrepresents a cyclic group, a hydroxy group, a mercapto group that may have oxo, or an amino group, Rrepresents a hydrogen atom, a hydrocarbon group, a hydroxy group, a mercapto group which may have oxo, or an amino group, or Rand Rmay link together to form a double bond, X represents a bond or a linear hydrocarbon group, W represents an oxygen atom or a sulfur atom, ring B represents a 5&#x2013;8 membered nitrogen-containing heterocyclic group, ring C represents a benzene ring, and&#x2014; represents a single bond or a double bond), or a salt or a prodrug thereof that has excellent neurodegenerative inhibitory activity and brain penetrability, and is useful as an agent for preventing/treating neurodegenerative diseases.

Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof

A compound represented by the formula (I):

Dihydrobenzofuran derivatives, process for the preparing thereof and agents

A compound represented by the formula:wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring B is benzene ring which is further substituted, Ring C is a dihydrofuran-ring which may be further substituted and R is hydrogen atom or an acyl group or a salt thereof has an excellent lipid peroxidation inhibitory activity and is useful as a lipid peroxidation inhibitor.

Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents

Crystalline acetoxymethyl and pivaloyloxymethyl esters of (+)-(5R, 6S)-6-[(R)-1-hydroxyethyl]-3-(3-pyridyl)-7-oxo-4-thia-1-azabicyclo-[3.2.0] hept-2-ene-carboxylic acid can be obtained by adding a poor solvent to a solution of acetoxymethyl or pivaloyloxymethyl ester of (+)-(5R, 6S)-6-[(R)-1-hydroxyethyl]-3-(3-pyridyl)-7-oxo-4-thia-1-azabicyclo-[3.2.0] hept-2-ene-carboxylic acid in a good solvent. The crystalline penem compounds obtained show improved stability and are useful antibacterial agents.

Crystalline esters of (+)-(5R,

Growing community of inventors

Osaka, Japan

Tetsuya Tsukamoto